14 February 2012 - ImpediMed (ASX: IPD) has entered a three year exclusive agency agreement with 3M to market ImpediMed’s L-Dex® lymphoedema products through its sales reps in Australia and New Zealand.
Lymphoedema of the arm remains a significant problem, even with the adoption of more conservative surgical procedures.
Despite recent advances in treating breast cancer, there is no known cure for lymphoedema.
Recognition and management of the condition – or a patient’s potential to develop the condition – as early as possible and providing effective treatment is crucial.
The agreement means that ImpediMed and 3M will work together with practitioners on early detection, treatment and accessibility. ImpediMed’s L-Dex® U400 device is a bioimpedance spectroscopy-based technology that aids in the clinical assessment of unilateral lymphoedema of the arm in women or the leg in women or men.
Clinicians now have a way to help assess which patients are developing lymphoedema so that proactive steps (including the use of 3M’s complementary technologies) can be taken to treat the condition.